دورية أكاديمية
أعرض في EDS

Adolescents and Young Adults With Sickle Cell Disease: Nociplastic Pain and Pain Catastrophizing as Predictors of Pain Interference and Opioid Consumption.

التفاصيل البيبلوغرافية
العنوان: Adolescents and Young Adults With Sickle Cell Disease: Nociplastic Pain and Pain Catastrophizing as Predictors of Pain Interference and Opioid Consumption.
المؤلفون: Kuisell C; Independent Researcher, Dumfries, VA., Ploutz-Snyder R; University of Michigan School of Nursing., Williams DA; University of Michigan Medical School, Ann Arbor, MI., Voepel-Lewis T; University of Michigan School of Nursing., Hutchinson RJ; University of Michigan Medical School, Ann Arbor, MI., Dudding KM; University of Alabama at Birmingham School of Nursing, Birmingham, AL., Bridges C; University of Alabama at Birmingham School of Nursing, Birmingham, AL., Lavoie Smith EM; University of Alabama at Birmingham School of Nursing, Birmingham, AL.
المصدر: The Clinical journal of pain [Clin J Pain] 2023 Jul 01; Vol. 39 (7), pp. 326-333. Date of Electronic Publication: 2023 Jul 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8507389 Publication Model: Electronic Cited Medium: Internet ISSN: 1536-5409 (Electronic) Linking ISSN: 07498047 NLM ISO Abbreviation: Clin J Pain Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [New York, N.Y.] : Raven Press, [c1985-
مواضيع طبية MeSH: Analgesics, Opioid*/therapeutic use , Anemia, Sickle Cell*/complications, Humans ; Adolescent ; Young Adult ; Pain Measurement ; Pain/etiology ; Pain/complications ; Catastrophization
مستخلص: Objectives: Some patients with sickle cell disease (SCD) have features of nociplastic pain. While research suggests that many patients with nociplastic pain consume more opioids due to opioid nonresponsiveness, little is known about the impact of nociplastic pain and pain catastrophizing on opioid consumption and pain interference among adolescents and young adults (AYA) with SCD. The purpose of this study was to (1) characterize nociplastic pain and pain catastrophizing among AYA with SCD, and (2) determine whether these characterizations are associated with subsequent opioid consumption and pain interference 1 month after characterization.
Methods: Participants completed surveys characterizing nociplastic pain and catastrophizing at a routine clinic visit (baseline). Thereafter, participants received weekly text messages that included pain interference and opioid consumption surveys. Multipredictor 2-part models were used to evaluate the predictive relationships between baseline characterizations and subsequent pain interference, and opioid consumption.
Results: Forty-eight AYA aged 14 to 35 completed baseline measures. Twenty-five percent of participants had scores suggestive of nociplastic pain. Greater nociplastic pain features significantly increased the odds of consuming opioids (odds ratio=1.2) and having greater interference from pain (odds ratio=1.46). Regression analyses found that greater baseline nociplastic pain characteristics were significantly associated with opioid consumption (β=0.13) and pain interference (β=0.061); whereas higher pain catastrophizing scores predicted less opioid consumption (β=-0.03) and less pain interference (β=-0.0007).
Discussion: In this sample of AYA with SCD, features of nociplastic pain predicted higher subsequent opioid consumption and pain interference. Being aware of nociplastic pain features in patients with SCD may better guide individualized pain management.
Competing Interests: Funding for this study was provided by the Hillman Advancing Early Research Opportunities Grant (The Rita & Alex Hillman Foundation, New York, NY), Rackham Graduate Student Research Grant (Rackham Graduate School, University of Michigan, Ann Arbor, MI), and the University of Michigan School of Nursing New Investigator Award (Ann Arbor, MI). C.K. received funding from the National Institute of Nursing Research (T32 NR016914). The authors declare no conflict of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11–16.
Vacca VM Jr, Blank L. Sickle cell disease: where are we now? Nursing. 2017;47:26–34.
Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4:2656–2701.
Uwaezuoke SN, Ayuk AC, Ndu IK, et al. Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. J Pain Res. 2018;11:3141–3150.
Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states-maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011;25:141–154.
Phillips K, Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum. 2013;65:291–302.
Martel MO, Wasan AD, Jamison RN, et al. Catastrophic thinking and increased risk for prescription opioid misuse in patients with chronic pain. Drug Alcohol Depend. 2013;132:335–341.
Martel MO, Jamison RN, Wasan AD, et al. The association between catastrophizing and craving in patients with chronic pain prescribed opioid therapy: a preliminary analysis. Pain Med. 2014;15:1757–1764.
Morasco BJ, Turk DC, Donovan DM, et al. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013;127:193–199.
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(suppl 3):S2–S15.
Campbell CM, Moscou-Jackson G, Carroll CP, et al. An evaluation of central sensitization in patients with sickle cell disease. J Pain. 2016;17:617–627.
Jacob E, Chan VW, Hodge C, et al. Sensory and thermal quantitative testing in children with sickle cell disease. J Pediatr Hematol Oncol. 2015;37:185–189.
Brandow AM, Panepinto JA. Clinical interpretation of quantitative sensory testing as a measure of pain sensitivity in patients with sickle cell disease. J Pediatr Hematol Oncol. 2016;38:288–293.
Dampier C. New and emerging treatments for vaso-occlusive pain in sickle cell disease. Expert Rev Hematol. 2019;12:857–872.
Ezenwa MO, Molokie RE, Wang ZJ, et al. Safety and utility of quantitative sensory testing among adults with sickle cell disease: indicators of neuropathic pain. Pain Pract. 2015;16:282–293.
Brandow AM, Stucky CL, Hillery CA, et al. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013;88:37–43.
Zempsky WT, Wakefield EO, Santanelli JP, et al. Widespread pain among youth with sickle cell disease hospitalized with vasoocclusive pain: a different clinical phenotype? Clin J Pain. 2017;33:335–339.
Brummett CM, Janda AM, Schueller CM, et al. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. Anesthesiology. 2013;119:1434–1443.
Corli O, Roberto A, Bennett MI, et al. Nonresponsiveness and susceptibility of opioid side effects related to cancer patients' clinical characteristics: a post-hoc analysis. Pain Pract. 2017;18:748–757.
Janda AM, As-Sanie S, Rajala B, et al. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. Anesthesiology. 2015;122:1103–1111.
Wasserman RA, Brummett CM, Goesling J, et al. Characteristics of chronic pain patients who take opioids and persistently report high pain intensity. Reg Anesth Pain Med. 2014;39:13–17.
Carroll CP, Lanzkron S, Haywood C, et al. Chronic opioid therapy and central sensitization in sickle cell disease. Am J Prev Med. 2016;51:S69–S77.
Grattan A, Sullivan MD, Saunders KW, et al. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10:304–311.
Jamison RN, Serraillier J, Michna E. Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res Treat. 2011;2011:941808–941808.
Mathur VA, Kiley KB, Carroll CP, et al. Disease-related, nondisease-related, and situational catastrophizing in sickle cell disease and its relationship with pain. J Pain. 2016;17:1227–1236.
Bakshi N, Lukombo I, Shnol H, et al. Psychological characteristics and pain frequency are associated with experimental pain sensitivity in pediatric patients with sickle cell disease. J Pain. 2017;18:1216–1228.
Graves JK, Jacob E. Pain, coping, and sleep in children and adolescents with sickle cell disease. J Child Adolesc Psychiatr Nurs. 2014;27:109–120.
Finan PH, Carroll CP, Moscou-Jackson G, et al. Daily opioid use fluctuates as a function of pain, catastrophizing, and affect in patients with sickle cell disease: an electronic daily diary analysis. J Pain. 2018;19:46–56.
Ruta NS, Ballas SK. The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med. 2016;17:1793–1798.
Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA. 2009;302:2479–2480.
Wakefield EO, Pantaleao A, Popp JM, et al. Describing perceived racial bias among youth with sickle cell disease. J Pediatr Psychol. 2018;43:779–788.
Green CR, Hart-Johnson T. The impact of chronic pain on the health of black and white men. J Natl Med Assoc. 2010;102:321–331.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–329.
Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain. 2009;10:777–791.
Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain. 2009;10:1113–1120.
Wolfe F. Fibromyalgianess. Arthritis Rheum. 2009;61:715–716.
As-Sanie S, Till SR, Schrepf AD, et al. Incidence and predictors of persistent pelvic pain following hysterectomy in women with chronic pelvic pain. Am J Obstet Gynecol. 2021;225:568.e1–568.e11.
Brummett CM, Urquhart AG, Hassett AL, et al. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol. 2015;67:1386–1394.
Basu N, Kaplan CM, Ichesco E, et al. Neurobiologic features of fibromyalgia are also present among rheumatoid arthritis patients. Arthritis Rheumatol. 2018;70:1000–1007.
Napadow V, LaCount L, Park K, et al. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum. 2010;62:2545–2555.
Häuser W, Jung E, Erbslöh-Möller B, et al. Validation of the Fibromyalgia Survey questionnaire within a cross-sectional survey. PLoS One. 2012;7:3–8.
Neville SJ, Clauw AD, Moser SE, et al. Association between the 2011 Fibromyalgia Survey Criteria and multisite pain sensitivity in knee osteoarthritis. Clin J Pain. 2018;34:909–917.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38:1113–1122.
Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7:524–532.
Osman A, Barrios FX, Kopper BA, et al. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997;20:589–605.
Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45(suppl 1):S3–S11.
Amtmann D, Cook KF, Jensen MP, et al. Development of a PROMIS item bank to measure pain interference. Pain. 2010;150:173–182.
Broderick JE, Schneider S, Junghaenel DU, et al. Validity and reliability of Patient-Reported Outcomes Measurement Information System instruments in osteoarthritis. Arthritis Care Res. 2013;65:1625–1633.
Opioid Conversion Calculator. Oregonpainguidance.org. 2023. Accessed August, 2019. https://www.oregonpainguidance.org/opioidmedcalculator/.
DosSantos MF, Martikainen IK, Nascimento TD, et al. Reduced basal ganglia μ-opioid receptor availability in trigeminal neuropathic pain: a pilot study. Mol Pain. 2012;8:74.
DaSilva AF, Nascimento TD, DosSantos MF, et al. Association of μ-opioid activation in the prefrontal cortex with spontaneous migraine attacks—brief report I. Ann Clin Transl Neurol. 2014;1:439–444.
StataCorp. Stata Statistical Software: Release 15. StataCorp LLC; 2017.
Fenske JN, Berland DW, Chandran S, et al. Ambulatory Pain Management Guideline. Michigan Medicine University of Michigan. https://michmed-public.policystat.com/policy/7109483/latest .
Belotti F, Deb P, Manning WG, et al. twopm: two-part models. Stata J. 2015;15:3–20.
Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983;78:605–610.
Wasserstein RL, Lazar NA. The ASA Statement on P -values: context, process, and purpose. Am Stat. 2016;70:129–133.
Barakat LP, Schwartz LA, Salamon KS, et al. A family-based randomized controlled trial of pain intervention for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2010;32:540–547.
Lemanek KL, Ranalli M, Lukens C. A randomized controlled trial of massage therapy in children with sickle cell disease. J Pediatr Psychol. 2009;34:1091–1096.
Moody K, Abrahams B, Baker R, et al. A randomized trial of yoga for children hospitalized with sickle cell vaso-occlusive crisis. J Pain Symptom Manage. 2017;53:1026–1034.
Schatz J, Schlenz AM, McClellan CB, et al. Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain. 2015;31:536–547.
Thomas LS, Stephenson N, Swanson M, et al. A pilot study: the effect of healing touch on anxiety, stress, pain, pain medication usage, and physiological measures in hospitalized sickle cell disease adults experiencing a vaso-occlusive pain episode. J Holist Nurs. 2013;31:234–247.
Gendreau M, Hufford MR, Stone AA. Measuring clinical pain in chronic widespread pain: selected methodological issues. Best Pract Res Clin Rheumatol. 2003;17:575–592.
Chan SWY, Goodwin GM, Harmer CJ. Highly neurotic never-depressed students have negative biases in information processing. Psychol Med. 2007;37:1281–1291.
Leppanen JM. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr Opin Psychiatry. 2006;19:34–39.
Campbell CM, Kronfli T, Buenaver LF, et al. Situational vs. dispositional measurement of catastrophizing: associations. J Pain. 2011;11:443–453.
Edwards RR, Campbell CM, Fillingim RB. Catastrophizing and experimental pain sensitivity: only in vivo reports of catastrophic cognitions correlate with pain responses. J Pain. 2005;6:338–339.
Barrett NJ, Ingraham KL, Vann Hawkins T, et al. Engaging African Americans in research: the recruiter’s perspective. Ethn Dis. 2017;27:453–462.
معلومات مُعتمدة: T32 NR016914 United States NR NINR NIH HHS
المشرفين على المادة: 0 (Analgesics, Opioid)
تواريخ الأحداث: Date Created: 20230421 Date Completed: 20230623 Latest Revision: 20240702
رمز التحديث: 20240702
مُعرف محوري في PubMed: PMC10330104
DOI: 10.1097/AJP.0000000000001119
PMID: 37083638
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5409
DOI:10.1097/AJP.0000000000001119